^
Association details:
| Biomarker: | MSI-H/dMMR + TMB-H + PD-L1 overexpression |
|---|---|
| Cancer: | Pancreatic Ductal Adenocarcinoma |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Near Complete Pathologic Response to PD-1 Inhibitor and Radiotherapy in a Patient with Locally Advanced Pancreatic Ductal Adenocarcinoma
Published date:
06/01/2021
Excerpt:
Tumor analysis with FoundationOne CDx (Foundation Medicine, Inc. Cambridge, MA) demonstrated a PD-L1 tumor proportion score of 70%, Microsatellite Instability–High (MSI-H) status, and a tumor mutational burden of 49 mutations per megabase...Interval CT scan after 2 cycles of pembrolizumab showed decreased mass size at 3.6×3.8×3.8cm. Serum CA 19–9 had decreased to 27.7 U/mL. Repeat imaging after a total of 4 cycles showed further tumor volume decrease (3.2×2.7×3.1 cm) and cystic degeneration...
DOI:
https://doi.org/10.2147/OTT.S311661
Test:
